Background-Neurofibromatosis type 1 (NF1) is a genetic disorder resulting from mutations in the NF1 tumor suppressor gene.
N eurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder resulting from mutations in the NF1 gene. NF1 encodes the protein neurofibromin, which negatively regulates p21 Ras (Ras) activity via stimulation of its GTPase function. 1 Germline mutations causing NF1 affect only 1 NF1 allele, although the loss of heterozygosity is described in primary tumor samples from NF1 patients. 2 Thus, haploinsufficiency of NF1 results in disease with complete penetrance and diverse clinical manifestations in different organ systems.
Clinical Perspective on p 1224
Common nonneoplastic manifestations of NF1 include cognitive disorders and skeletal abnormalities, 2 whereas cardiovascular disease (CVD) is a serious but underrecognized complication, contributing to significant increases in morbidity and premature mortality. 3, 4 In particular, the aorta and proximal branches demonstrate increased aneurysm formation and exaggerated intimal hyperplasia. 5 The frequency of NF1 vasculopathy is difficult to define because of a lack of routine screening; however, the prevalence of vascular lesions in large clinical series approaches 7%. [5] [6] [7] Specifically, a study of 31 NF1 patients with a diagnosis of vascular disease identified 38 aneurysms among the group, with an average age at diagnosis of 38 years (range, 3-77). 5 Studies using mouse models that recapitulate NF1 vaso-occlusive disease revealed that neurofibromin-deficient myeloid cells and vascular smooth muscle cells (VSMCs) cooperate to induce neointima hyperplasia after arterial injury. [8] [9] [10] Correlative studies demonstrate that NF1 patients have evidence of chronic inflammation and mobilization of a specific monocyte subset in their peripheral blood that is linked to vaso-occlusive disease progression and aneurysm formation in non-NF1 patients with CVD. 8, 11 Despite these observations, the pathogenesis of NF1 aneurysm disease is unknown, in part, because of a lack of animal models that mimic the human disease. Given the mostly silent presentation of aneurysms in NF1 patients and the potential for catastrophic rupture, understanding disease pathogenesis is critical for aneurysm prevention, early detection, and treatment.
In this study, we used an established mouse model of aneurysm formation and cell lineage-restricted transgenic mice to test the role of Nf1 haploinsufficiency (Nf1 +/-) in various cell types on aneurysm formation. We provide evidence that heterozygous inactivation of Nf1 directly contributes to larger and more severe aneurysms with enhanced oxidative species production and matrix metalloproteinase-9 (MMP-9) activation. Further, lineage-restricted inactivation of a single Nf1 gene copy in myeloid cells, but not VSMCs, is sufficient for aneurysm formation, thereby implicating Nf1 +/myeloid cells as the cellular triggers for Nf1 +/aneurysm formation in vivo. Finally, we provide pharmacological evidence that aneurysm formation in Nf1 +/mice is abrogated by daily low-dose administration of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin, which has antioxidant and anti-inflammatory effects. To further delineate the pharmacological effects of simvastatin, Nf1 +/mice were treated with the antioxidant apocynin, which also reduced aneurysm formation. Thus, we generated a novel model of NF1-associated aneurysmal disease and provide genetic evidence that Nf1 +/myeloid cells are critical mediators of aneurysm formation via an antioxidant-sensitive pathway, suggesting a potential therapeutic target.
Methods

Animals
All protocols were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee. Nf1 +/mice were obtained from Tyler Jacks (Massachusetts Institute of Technology, Cambridge) and backcrossed 13 generations into the C57BL/6J strain. Nf1 flox/flox mice were obtained from Luis Parada (University of Texas Southwestern Medical Center, Dallas) and backcrossed 13 generations into the 129SvJ strain. LysMcre (stock 4781) and SM22cre (stock 4746) mice were purchased from Jackson Laboratory (Bar Harbor, ME). Nf1 fl/fl mice were intercrossed with LysMcre or SM22cre mice to generate F1 C57BL/6×129SvJ progeny. Cre-mediated recombination was confirmed by polymerase chain reaction. 12 LacZ lineage tracing of aortas from Nf1 fl/+ ;Rosa26 fl/+ ;Sm22cre mice revealed staining limited to the vessel media where VSMCs reside (data not shown). LacZ lineage tracing of aortas from Nf1 fl/+ ;Rosa26 fl/+ ;LysMcre mice revealed sparse staining limited to the vessel adventitia (data not shown). Nf1 fl/fl 129SvJ mice intercrossed with Nf1 +/-C57BL/6 mice generated F1 Nf1 +/and wild-type (WT) control animals. Genotyping was performed as previously described. 9
Angiotensin II-Infused Abdominal Aortic Aneurysm Model
Twelve-week-old control and experimental male mice were infused with angiotensin II (AngII, 1500 ng•kg -1 •min -1 , Calbiochem) or saline for 35 days, as described, 13 with modification. Animals were anesthetized by inhalation of 2% isoflurane, and an osmotic pump (2006, Durect Corporation) containing AngII or saline was implanted subcutaneously. At indicated time points, a portion from the aortic arch to the iliac arteries was excised for analysis.
Classification and Quantification of Aneurysms
Images of arteries were obtained on a stereo-microscope (Carl Zeiss Inc). The maximum external arterial diameters were measured using Metamorph 6.1 (Universal Imaging Systems Corp). Aneurysms were defined as an increase in the external aortic diameter of ≥50% in comparison with control animals. Aortic aneurysm severity was rated from type 0 to type IV according to the method of Martin-McNulty et al 14 with modification: type 0, no aneurysm; type I, dilation 1.5 to 2 times the diameter of a normal artery; type II, a single dilation that is >2 times the diameter of a normal artery; type III, multiple dilations with the largest being 1.5 to 2 times the diameter of a normal artery; and type IV, multiple dilations with the largest being >2 times the diameter of a normal artery.
Simvastatin and Apocynin Administration
Simvastatin (1 mg•kg -1 •d -1 , Besse) was administered in water via oral gavage beginning 7 days before AngII or saline infusion and continued throughout the experiment. Apocynin (also known as acetovanillone, 100 mg•kg -1 •d -1 , Acros Organics) was administered in drinking water beginning 7 days before AngII or saline infusion and continued throughout the experiment. Control mice received water at a similar volume.
Statistical Analysis
Quantitative results are shown as mean±standard error of the mean. All statistical analyses were performed by using Prism 5 (GraphPad Software). P values were obtained by the unpaired Student t test when comparing 2 groups and by 1-way analysis of variance followed by Tukey analysis when comparing ≥3 groups. P<0.05 was considered significant. To determine the significance of categorical data, the Fisher exact test was used with Bonferroni correction.
Results
Heterozygous Inactivation of Nf1 Amplifies the Incidence and Severity of Aneurysm Formation in Angiotensin II-Infused Mice
To test the hypothesis that Nf1 heterozygosity enhances aneurysm formation in vivo, WT and Nf1 +/mice were infused with AngII to induce aneurysms. The infusion of AngII induces inflammatory mediators and reactive oxygen species (ROS) within the arterial wall, producing abdominal aortic aneurysms (AAA) that recapitulate human lesions. 15 Infusion of AngII increased aneurysm formation 3-fold in Nf1 +/mice in comparison with WT mice ( Figure 1A and 1B). Morphometric analysis of abdominal aortas from both genotypes revealed that AngII-infused Nf1 +/mice had significantly larger aneurysms ( Figures 1C and 2A ). Further, Nf1 +/aneurysms were more severe than WT aneurysms quantitatively, with increased degradation of the elastic lamina and disorganized architecture, which is reminiscent of lesions from NF1 patients ( Figures 1D, 2B , and 2D). 16 Importantly, AngII infusion did not alter body weight or intra-arterial blood pressure in either genotype (data not shown). Saline-infused Nf1 +/and WT mice did not form aneurysms ( Figures 1A, 1B , and 2A). These data indicate that Nf1 heterozygosity augments AngII-induced aneurysm formation.
Nf1 +/-Aneurysms Are Characterized by Inflammatory Cell Infiltration, VSMC Expansion, and ROS Production
NF1 patients and Nf1 +/mice have increased populations of circulating inflammatory monocytes and proinflammatory cytokines linked to aneurysm formation. 8, 9 Therefore, we sought to characterize the cellular and structural composition of WT and Nf1 +/aneurysms. Histological examination of Nf1 +/aneurysms demonstrated significant dilation and degradation of the aorta, including increased disruption of the elastic lamina and adventitial expansion in comparison with WT aneurysms (Figure 2A through 2E). Importantly, Nf1 +/aneurysms contained 4 times the number of macrophages in comparison with WT ( Figure 2C and 2E). Infiltrating T cells, mast cells, and neutrophils were increased in both Nf1 +/and WT aneurysms, but accounted for <5% of all cells and did not differ between genotypes (data not shown). Importantly, Nf1 +/macrophages colocalized to sites of elastic lamina degradation, medial rupture, and adventitial expansion, indicating their potential role in aneurysm formation ( Figure 2B and 2C). AngII infusion also induced a significant expansion of VSMCs in the media of Nf1 +/aortas in comparison with WT ( Figure IA and IB in the online-only Data Supplement). Nf1 +/-VMSC expansion is consistent with previous findings that Nf1 +/-VSMCs exhibit increased proliferation and migration in response to cytokines secreted by macrophages and vascular wall cells implicated in CVD. 9, 17 Finally, costaining with α-smooth muscle actin and anti-Mac-3 illustrated that VSMC expansion was within and near the vessel media, whereas macrophage infiltration was primarily in the adventia ( Figure  IC in the online-only Data Supplement).
Genetic studies demonstrate that VSMC and macrophage secretion of MMPs and ROS are important molecular triggers for extracellular matrix remodeling and aneurysm induction. 18 Figure 1 . Nf1 +/mice have enhanced AngII-induced AAA formation. A, Representative photographs of the aorta and branches from salineor AngII-infused WT and Nf1 +/mice. Boxes identify the areas magnified in the lower photographs. Scale bars, 1 mm. B, Quantification of aneurysm incidence. *P<0.0083 for saline-infused WT (n=24) vs AngII-infused WT (n=29) and AngII-infused Nf1 +/-(n=31). **P<0.0083 for saline-infused Nf1 +/-(n=16) vs AngII-infused Nf1 +/-. Analysis by Fisher exact test with Bonferroni correction. C, Maximum abdominal aortic diameter of saline-or AngII-infused WT and Nf1 +/mice. Clustering around 1 mm represents animals without aneurysm formation. *P<0.05 for saline-infused Nf1 +/-(n=16) vs AngII-infused Nf1 +/-(n=31). **P<0.05 for AngII-infused WT (n=29) vs AngII-infused Nf1 +/-(n=31). No statistical significance was observed for saline-infused WT (n=24) vs AngII-infused WT (n=29). Analysis by 1-way ANOVA with the Tukey test. Error bars=mean±SEM. D, Aneurysm severity for AngII-infused WT (n=29) or AngII-infused Nf1 +/-(n=31) mice. No aneurysms formed in saline-infused mice of either genotype. AAA indicates abdominal aortic aneurysms; AngII, angiotensin II; ANOVA, analysis of variance; SEM, standard error of the mean; and WT, wild type. March 18, 2014
Given the increased density of VSMCs and macrophages in Nf1 +/aneurysms, we measured expression and activation of MMP-2 and MMP-9 in aortas harvested from Nf1 +/and WT mice infused with AngII or saline. AngII infusion increased both MMP-2 and MMP-9 activity and preferentially amplified MMP-9 expression in Nf1 +/aneurysms in comparison with AngII-infused WT aneurysms as determined by in situ zymography and immunohistochemistry ( Figure 3A ). In addition, gelatin zymography of abdominal aortic explants from AngII-infused WT and Nf1 +/mice corroborated increases of MMP-2 and MMP-9 in both genotypes with significantly enhanced activation of MMP-9 in Nf1 +/aortas ( Figure 3B ). Amplified MMP-9 expression in Nf1 +/aortas is an important observation, because MMP-9 is largely derived from vessel wall macrophages, 19 which is consistent with the increased macrophage infiltration observed in Nf1 +/aneurysms. We next assessed ROS production in abdominal aortic crosssections from AngII-and saline-infused Nf1 +/and WT mice with dihydroethidium, a superoxide probe. AngII infusion significantly increased superoxide production in Nf1 +/aortas in comparison with WT aortas, whereas superoxide production was nearly undetectable in the aortas from saline-infused Nf1 +/and WT aortas ( Figure 3C and 3D ). Collectively, these data demonstrate that Nf1 heterozygous aneurysms have evidence of increased inflammatory cell infiltration, MMP activation, and ROS production, which are linked to abnormal arterial remodeling and disease progression.
Heterozygous Inactivation of Nf1 in Myeloid Cells Alone Is Sufficient to Recapitulate Nf1 +/-Aneurysm Formation
Nf1 +/mice have increased aneurysm formation characterized by increased macrophages and VSMCs and their secretory products that promote disease progression. Based on these observations, we generated transgenic mice with a single copy of the Nf1 gene ablated in VMSCs or myeloid cells alone to determine the role of Nf1 heterozygosity in VSMCs and macrophages on aneurysm formation. In brief, Nf1 fl/fl mice containing conditional Nf1 alleles susceptible to Cre-mediated recombination were intercrossed with SM22cre or LysMcre transgenic mice, generating Nf1 fl/+ ;SM22cre and Nf1 fl/+ ;LysMcre progeny. Nf1 fl/fl mice underwent efficient Cre-mediated recombination when crossed with LysMcre ( Figure IIF in the online-only Data Supplement) or SM22cre mice. 10 LysMcre-mediated recombination was seen in the aortic adventia, a known location for macrophages, whereas the aortic media showed minimal recombination.
Nf1 fl/+ ;SM22cre and Nf1 fl/+ ;LysMcre mice were infused with AngII or saline and evaluated for aneurysm formation along with littermate controls (WT and Nf1 +/mice). Nf1 fl/+ ;LysMcre mice infused with AngII developed large aneurysms recapitulating the phenotype of Nf1 +/mice, whereas Nf1 fl/+ ;SM22cre mice produced less severe aneurysms similar to WT mice ( Figure 4A through 4D ). Specifically, a 2.5-fold increase in AAA incidence was observed in Nf1 fl/+ ;LysMcre mice in comparison with Nf1 fl/+ ;SM22cre and WT mice ( Figure 4B ). Saline infusion failed to produce aortic aneurysms in all genotypes (data not shown). Additionally, AngII-infused Nf1 fl/+ ;LysMcre aneurysms displayed similar maximal dilation and aneurysm severity in comparison with Nf1 +/mice ( Figure 4C and 4D) .
Histological examination of hematoxylin and eosin-and van Gieson-stained arterial cross-sections of Nf1 fl/+ ;LysMcre aneurysms revealed increased elastic lamina degradation and adventitial expansion, similar to aneurysms harvested from AngII-infused Nf1 +/mice ( Figure IIA Figure 4E ). Similar to Nf1 +/mice, macrophages in Nf1 fl/+ ;LysMcre mice were in close proximity to areas of adventitial expansion and elastic lamina degradation ( Figure 4E and Figure IIB in the online-only Data Supplement). Additionally, Nf1 fl/+ ;LysMcre and Nf1 fl/+ ;SM22cre displayed MMP activity and dihydroethidium staining similar to Nf1 +/and WT mice, respectively ( Figure IID and IIE in the online-only Data Supplement). Collectively, these data provide genetic evidence that heterozygous inactivation of Nf1 in myeloid cells alone is sufficient to recapitulate Nf1 +/aneurysm formation in vivo, thereby implicating Nf1 +/macrophages as the cellular trigger for aneurysm formation.
Simvastatin Attenuates AngII-Induced AAA Formation in Nf1 +/-Mice
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
are clinically efficacious in the prevention of several manifestations of CVD, including aneurysm formation, 20 which is in part attributable to their anti-inflammatory and antioxidant function. 21 Recent studies have shown that daily statin therapy reduces arterial stenosis in Nf1 +/mice, in part, by inhibiting macrophage functions central to disease progression. 9 Therefore, we tested whether simvastatin would reduce Nf1 +/aneurysm formation given our experimental observations. WT and Nf1 +/mice were treated with daily low-dose simvastatin (1 mg•kg -1 •d -1 ) or water for 7 days before the initiation of AngII infusion and continued for 35 days. Low-dose simvastatin reduced AAAs in AngII-infused Nf1 +/mice by >2-fold in comparison with water-treated controls ( Figure 5A and 5B) without affecting blood pressure or serum cholesterol levels (data not shown). Corresponding decreases in aortic diameter and severity in AngII-infused Nf1 +/mice were also observed ( Figure 5C and 5D ). There was no significant difference in AAA incidence, maximum aortic diameter, or severity in AngII-infused WT mice in either treatment group (Figure 5A  through 5D ). Further, simvastatin treatment reduced arterial remodeling, macrophage infiltration ( Figure IIIA and IIIB in the online-only Data Supplement) MMP-9 expression and activation, and ROS production ( Figure IVA through IVD in the online-only Data Supplement) in arterial cross-sections from Nf1 +/mice in comparison with water treatment. These results demonstrate that simvastatin prevents AngII-induced AAA formation in Nf1 +/mice, providing a potential therapeutic for NF1 aneurysmal disease.
Apocynin Attenuates AngII-Induced AAA Formation in Nf1 +/-Mice
Increased production of ROS has been demonstrated in several animal models of CVD, and antioxidant therapy has shown some utility in reversing many of these processes. 22 Based on our observation that Nf1 +/aortas have evidence of increased ROS in response to AngII infusion, we sought to explore the role of antioxidant therapy, using apocynin, in attenuating Nf1 +/aneurysm formation. Although generally recognized as a nonspecific antioxidant, recent evidence suggests that apocynin may inhibit superoxide production in cells containing myeloperoxidase, including macrophages and monocytes. 23, 24 WT and Nf1 +/mice were treated with apocynin for 7 days before initiation of AngII infusion and continued for 35 days thereafter. Apocynin reduced AAAs in AngII-infused Nf1 +/mice by >2-fold in comparison with water-treated controls, whereas apocynin did not have a significant effect on WT mice ( Figure 6A and 6B ). Additionally, decreases in both maximum abdominal aortic diameter and aneurysm severity were also noted in apocynin-treated Nf1 +/mice, whereas apocynin-treated WT mice did not display a difference in either parameter ( Figure 6C and 6D) . Remodeling of the arterial wall, macrophage infiltration, and ROS production was significantly reduced in apocynin-treated Nf1 +/mice in comparison with water-treated controls ( Figure VA through VD in the online-only Data Supplement). These results identify overproduction of ROS as a significant contributor to Nf1 +/aneurysm formation and provide evidence that antioxidants may be a viable therapeutic option.
Discussion
Cardiovascular disease is a nonneoplastic manifestation in NF1 patients that contributes to debilitating morbidities and early mortality. 3, 4 Many of these vascular pathologies, including aneurysm formation and arterial stenosis, are often clinically silent until a catastrophic event, making an accurate measure of disease burden difficult to determine. Thus, understanding the pathogenesis of NF1 vasculopathy is critical to facilitate appropriate CVD screening, early recognition, and targeted intervention in NF1 patients.
A major limitation in understanding NF1 aneurysmal disease has been the lack of an animal model that closely recapitulates the human disease. In this study, we present a murine model of NF1 aneurysmal disease, which provides a novel approach to examine the cellular mechanisms that regulate NF1 aneurysm formation. Analysis of Nf1 +/aneurysms revealed increased macrophage infiltration, MMP-9 expression and activation, and ROS production, which are molecular and cellular signatures of aneurysm formation observed in other experimental animal models independent of neurofibromin deficiency. 19, 25 These observations suggest that vascular inflammation and macrophage secretory products are critical factors in NF1 aneurysmal disease, which is consistent with aneurysm formation in other chronic inflammatory diseases. 25, 26 This is an important observation, because we previously demonstrated that NF1 patients without known CVD have increased numbers of a specific subset of circulating inflammatory monocytes and cytokines 8 that have been previously linked to vascular disease in non-NF1 subjects in large-population studies. 11 Figure 5 . Preventive effect of simvastatin on AngII-induced AAA formation in Nf1 +/mice. A, Representative photographs of abdominal aortas from water or simvastatin-treated, AngII-infused WT and Nf1 +/mice. Scale bars, 1 mm. B, Quantification of aneurysm incidence in water-or simvastatin-treated, AngII-infused mice. C, Maximum abdominal aortic diameter of water or simvastatin-treated, AngII-infused WT and Nf1 +/mice. Clustering around 1 mm represents animals without aneurysm formation. *P<0.05 for water-treated WT (n=17) vs water-treated Nf1 +/-(n=22). **P<0.05 for water-treated Nf1 +/vs simvastatin-treated Nf1 +/-(n=10). Analysis by 1-way ANOVA with the Tukey test. Error bars=mean±SEM. For B and C, no statistical significance was observed for water-treated WT vs simvastatin-treated WT (n=13). D, Severity index of AAAs of AngII-infused WT and Nf1 +/mice treated with water (WT, n=17; Nf1 +/-, n=22) or simvastatin (WT, n=9; Nf1 +/-, n=10). For B through D, saline-infused WT or Nf1 +/mice in either treatment group did not form aneurysms. AAA indicates abdominal aortic aneurysms; AngII, angiotensin II; ANOVA, analysis of variance; SEM, standard error of the mean; and WT, wild type.
To determine the contribution of neurofibromin-deficient myeloid cells to Nf1 +/aneurysm formation, we used lineage-restricted transgenic mice to specifically ablate a single Nf1 allele in myeloid cells alone. Heterozygous inactivation of the Nf1 gene in myeloid cells was sufficient to reproduce the aneurysm phenotype observed in Nf1 +/mice infused Figure 6 . Preventive effect of apocynin on AngII-induced AAA formation in Nf1 +/mice. A, Representative photographs of abdominal aortas from water or apocynin-treated, AngII-infused WT and Nf1 +/mice. Scale bars, 1 mm. B, Quantification of aneurysm incidence in water-or apocynin-treated, AngII-infused mice. *P<0.0083 for water-treated Nf1 +/-(n=23) vs apocynin-treated Nf1 +/-(n=26). Analysis by Fisher exact test with Bonferroni correction. C, Maximum abdominal aortic diameter of water-or apocynin-treated, AngII-infused WT and Nf1 +/mice. Clustering around 1 mm represents animals without aneurysm formation. *P<0.05 for water-treated WT (n=14) vs watertreated Nf1 +/-(n=23). **P<0.05 for water-treated Nf1 +/vs apocynin-treated Nf1 +/-(n=26). Analysis by 1-way ANOVA with the Tukey test. Error bars=mean±SEM. For B and C, no statistical significance was observed for water-treated WT versus apocynin-treated WT (n=24). D, Severity index of AAAs of AngII-infused WT and Nf1 +/mice treated with water (WT, n=14; Nf1 +/-, n=23) or apocynin (WT, n=24; Nf1 +/-, n=26). For B through D, saline-infused WT or Nf1 +/mice in either treatment group did not form aneurysms. AAA indicates abdominal aortic aneurysms; AngII, angiotensin II; ANOVA, analysis of variance; SEM, standard error of the mean; and WT, wild type. March 18, 2014 with AngII. Importantly, despite significant expansion of Nf1 +/-VSMCs in arterial walls, aneurysm frequency and severity in transgenic mice harboring a single Nf1 allele in VSMCs alone were similar to WT controls. Additionally, administration of simvastatin, a statin with potent anti-inflammatory and antioxidant effects, diminished aneurysm formation in Nf1 +/mice. Finally, the antioxidant apocynin efficiently reduced Nf1 +/aneurysm formation. Collectively, these data directly implicate neurofibromin-deficient myeloid cells as the critical cellular effectors of aneurysm formation in Nf1 +/mice and indicate ROS as a therapeutic target to prevent or treat NF1 aneurysm formation.
Neurofibromin negatively regulates the Ras signaling cascade in multiple cell types by accelerating the conversion of active Ras-GTP to its inactive GDP confirmation. 1 Loss of neurofibromin activates Ras and its downstream effectors, including the Ras-Mek-Erk and Ras-PI-3K pathways, rendering cells hypersensitive to diverse growth factors, contributing to the complexity of disease manifestations observed in NF1 patients. 2, 8, 9, 17 Interestingly, myeloid progenitor cells are particularly sensitive to Ras activation and demonstrate multiple gain-of-function phenotypes contributing to myeloproliferative disease, plexiform neurofibroma formation, bone disease, and vaso-occlusive disease in animal models of NF1 disease. 8, 9, [27] [28] [29] Relevant to the current study, myeloid cells secrete growth factors and cytokines that are mediators of CVD, including vessel occlusion and aneurysm formation. 9, 30 In view of our recent report that neurofibromin-deficient myeloid cells are the primary mediators of Nf1 +/arterial stenosis, 9 the observation that mice with heterozygous inactivation of Nf1 in myeloid cells alone form aneurysms at a similar incidence to Nf1 +/mice highlights the global pathogenic consequences of neurofibromin-deficient myeloid cells to diverse NF1 clinical manifestations, including CVD.
Myeloid cell recruitment and infiltration of the vessel wall to initiate elastic lamina degradation are essential steps in aneurysm formation. 25 AngII facilitates aneurysm formation via activation of monocytes and other leukocytes, which secrete cytokines and chemotactic factors leading to enhanced macrophage production of MMPs, resulting in vascular inflammation and vessel wall remodeling. 31 Although several molecular ligand-receptor signaling cascades contribute to the progression of aneurysmal disease, pharmacological inhibition or genetic disruption of monocyte chemotactic protein-1 binding to its primary receptor, CCR2, reduces aneurysm formation and MMP-2 and MMP-9 activation, as well. [31] [32] [33] This signaling axis is particularly interesting because our laboratory recently demonstrated that myeloid cell heterozygosity mobilized Ly6C hi monocytes in peripheral blood, 9 which are the murine correlate of human proinflammatory monocytes and coexpress high cell surface levels of the CCR2 receptor. 34, 35 Whether Nf1 +/macrophages are mobilized from the bone marrow via the monocyte chemotactic protein-1/CCR2 axis or proliferate locally within the aortic wall from the recently described common myeloid progenitor remains to be elucidated. 31, 36 Another striking observation in our study is the increased production of ROS and MMPs in Nf1 +/vessel walls and developing aneurysms. ROS and MMP production by various cell types is critical for aneurysm formation in several model systems. Genetic or pharmacological disruption of MMP-2 and MMP-9 in mice decreases aneurysm formation. 37 These findings suggest that MMPs, released by resident and infiltrating vascular wall cells, are key molecular events in aneurysm formation. Given these observations, our study suggests that increased levels of MMP-9 observed in Nf1 heterozygous aneurysms may play a significant role in NF1 aneurysm progression, warranting further investigation to examine whether genetic modification and pharmacological inhibition of MMP-9 activity can inhibit aneurysm progression in our Nf1 experimental system.
Increased ROS levels are also detected in human and murine cardiovascular lesions including aneurysms. 38, 39 Moreover, evidence suggests that ROS overproduction facilitates MMP activation and contributes to vascular inflammation and vessel wall remodeling. 40 Neurofibromin directly stimulates the adenylyl cyclase/cAMP pathway, whereas loss of neurofibromin amplifies mitochondrial ROS production in Drosophila melanogaster. 41 Conversely, constitutively active Ras mutations dramatically increase ROS production in mammalian hematopoietic progenitor cells via NAD(P)H oxidase (NOX) activation without increasing mitochondrial ROS. 42 Additionally, we have found that simvastatin and apocynin, which both have antioxidant properties, reduce Nf1 +/aneurysms, implicating oxidative stress as a major contributor to neurofibromin-deficient aneurysm formation. 21, 23 Further investigation using complex transgenic mice and targeted pharmacotherapies will now be needed to explore the redox balance in neurofibromin-deficient cells and to determine the source of ROS in aneurysm pathogenesis.
Previous studies have also identified increased expression of ROS-producing NOX subunits p22 phox and p47 phox within aortic aneurysms of non-NF1 patients and mice. 38, 43 Genetic disruption of p47 phox significantly diminishes oxidative stress and subsequent aneurysm formation in mice infused with AngII. 26 These data suggest a role of NOX proteins as producers of ROS in aneurysm pathogenesis, indicating potential sources for observed Nf1 +/-ROS production. Interestingly, Heumuller et al 23 extensively studied apocynin's ability to reduce ROS in infiltrating and resident vascular wall cells, concluding that apocynin is dimerized and activated in myeloperoxidase-expressing cells, including macrophages and granulocytes. Apocynin's dimerized form is believed to inhibit the binding of the p47 phox cytosolic subunit to the membranebound gp91 phox subunit, therefore inhibiting the formation of the active NOX2 complex. 44 These studies provide a rationale for transgenic murine studies using cell-specific deletion of p47 phox and gp91 phox within endothelial cells, VSMCs, and monocytes/macrophages in Nf1 +/mice to test whether specific NOX isoform(s) contribute to ROS overproduction and aneurysm development. These studies are currently underway in our laboratory to identify specific therapeutic targets for preventing and treating NF1 vascular disease.
Statins are efficacious in reducing inflammation and oxidative stress independent of their lipid-lowering capacity in both human trials and animal models. 21 Additionally, statins have a safety profile that makes them advantageous for use in pediatric patients, as evidenced by recent trials in NF1 children, 45 which may be important because evidence of vascular inflammation was identified in adolescent NF1 patients. 8 In the current study, simvastatin reduced Nf1 +/aneurysm formation with corresponding attenuation of MMP-9 activation and ROS production, lending evidence to the role of inflammation and oxidative stress in NF1 aneurysm development. Finally, treatment with the antioxidant apocynin, which produced results similar to simvastatin, indicates that a reduction of oxidative stress may mediate the therapeutic effect simvastatin has on reducing Nf1 +/aneurysm formation. Based on our preclinical findings that low-dose statin treatment attenuates aneurysm formation and vaso-occlusive disease, 9 it is possible that statins or more general antioxidants could be a viable therapeutic intervention in NF1 patients for the prevention and treatment of CVD.
In sum, this study establishes the first animal model of NF1 aneurysm disease and identifies Nf1 heterozygous myeloid cells as the cellular effectors of Nf1 +/aneurysm formation. In addition, we provide significant evidence that oxidative stress partially mediates Nf1 +/aneurysm formation and may be a viable therapeutic target. We provide a new model of NF1 vasculopathy that will serve as a tractable platform for understanding disease pathogenesis, the identification of novel biomarkers of preclinical disease, and the development of novel therapeutics for the prevention and treatment of NF1 aneurysm formation. 
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